cytarabine has been researched along with verapamil in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mattern, J; Pommerenke, EW; Traugott, U; Volm, M | 1 |
| Appelt, M; Büchner, T; Eichelbaum, M; Grille, W; Hiddemann, W; Hossfeld, DK; Koslowski, B; Kraft, J; Kuse, R; Quabeck, K | 1 |
| Ho, AD; Hunstein, W; Trümper, LH; Wulf, G | 1 |
| Dalton, WS; Hoeltge, GA; Slovak, ML; Trent, JM | 1 |
| Broggini, M; D'Incalci, M; Geroni, C; Giuliani, FC; Grandi, M; Ubezio, P | 1 |
| Campbell, J; Mayhew, E; Radel, S; Rustum, YM | 1 |
| Hayashi, M; Honma, Y; Hozumi, M; Okabe-Kado, J; Tsuruo, T | 1 |
| Belloc, F; Boiron, JM; Cony-Makhoul, P; Dubosc-Marchenay, N; Dumain, P; Fabères, C; Lacombe, F; Marit, G; Montastruc, M; Puntous, M | 1 |
| Audouin, J; Bernadou, A; Chauvenet, L; Ciaudo, M; Favier, R; Horellou, MH; Rossert, J; Samama, M | 1 |
| Anagnostopoulos, N; Androutsos, G; Galanopoulos, A; Kalmantis, T; Meletis, J; Paterakis, G; Rombos, Y; Sagriotis, A; Symeonidis, A; Tiniakou, M; Tsimberidou, AM; Yataganas, X; Zoumbos, N | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Takeshita, A | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Guo, C; Han, Y; Li, Y; Meng, X; Shen, Z; Wan, L; Yang, Q; Yu, Q; Zhou, Z | 1 |
2 review(s) available for cytarabine and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
2 trial(s) available for cytarabine and verapamil
| Article | Year |
|---|---|
Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cytarabine; Daunorubicin; Hemodynamics; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Thioguanine; Verapamil | 1990 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
16 other study(ies) available for cytarabine and verapamil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Reversal of multidrug resistance with (R)-verapamil in vitro and in vivo].
Topics: Animals; Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Resistance; Female; Leukemia L1210; Mice; Stereoisomerism; Thymidine; Tumor Cells, Cultured; Uridine; Verapamil | 1991 |
Addition of verapamil to overcome drug resistance in multiple myeloma: preliminary clinical observations in 10 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Drug Resistance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Verapamil; Vincristine | 1989 |
Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Doxorubicin; Drug Resistance; Humans; Membrane Glycoproteins; Tumor Cells, Cultured; Verapamil | 1988 |
Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.
Topics: Adenocarcinoma; Cell Line; Cell Survival; Cisplatin; Colonic Neoplasms; Cytarabine; Dactinomycin; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Resistance; Flow Cytometry; Humans; Verapamil | 1988 |
Approaches to overcome in vivo anti-cancer drug resistance.
Topics: 3-Deazauridine; Animals; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Cell Line; Cytarabine; Doxorubicin; Drug Resistance; Drug Synergism; Fluorouracil; Leucovorin; Leukemia L1210; Liposomes; Mice; Verapamil | 1986 |
Effects of inducers of erythroid differentiation of human leukemia K562 cells on vincristine-resistant K562/VCR cells.
Topics: Animals; Butyrates; Butyric Acid; Cell Differentiation; Cells, Cultured; Cytarabine; Dactinomycin; Doxorubicin; Drug Resistance; Erythropoiesis; Hemin; Humans; Leukemia, Experimental; Mitomycins; Verapamil; Vincristine | 1983 |
Daunorubicin (DNR) accumulation in fresh leukemic cells: correlation with clinical and biological features.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Stimulation, Chemical; Treatment Failure; Verapamil | 1994 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Ifosfamide; Inappropriate ADH Syndrome; Lymphoma, T-Cell, Peripheral; Methotrexate; Mitoguazone; Prednisone; Teniposide; Verapamil; Vincristine; Vindesine | 1995 |
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Calcium Channel Blockers; Carbocyanines; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Genistein; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Probenecid; Prognosis; Prospective Studies; Rhodamine 123; Survival Analysis; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Verapamil | 2002 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Cell Line, Tumor; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Paclitaxel; Verapamil; Xenograft Model Antitumor Assays | 2013 |